Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 17371907.
- Also identified by PMC identifier 2117666.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The role of amyloid metabolism in the pathophysiology of frontotemporal lobar degeneration (FTLD) has yet to be elucidated. We compared CSF levels of amyloid beta 1-40 (Abeta40) and amyloid beta 1-42 (Abeta42) in patients with FTLD (n = 21) versus patients with Alzheimer's disease (AD, n = 39) and in control subjects (n = 30). While in AD cases Abeta42 levels were lower and CSF Abeta40 levels equal to those in controls, a significant decrease in Abeta40 and increase in the CSF Abeta42/Abeta40 ratio was observed in FTLD compared with AD and control subjects. These findings favour a differential involvement of amyloid beta peptides in FTLD compared with AD.
Medical subject headings
- Alzheimer Disease
- Amyloid beta-Peptides
- Dementia
- Peptide Fragments